
    
      This is a Phase I/II, multi-center, open label, multiple-dose, first in human study, designed
      to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or
      recommended Phase 2 dose (RP2D) for EMB-06 in patients with relapsed or refractory multiple
      myeloma. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be
      assessed.
    
  